Compulsory License On Table In UK For Orkambi

01:02 EDT 13 Jun 2019 | Elsevier Business Intelligence

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory l...

Original Article: Compulsory License On Table In UK For Orkambi


More From BioPortfolio on "Compulsory License On Table In UK For Orkambi"

Quick Search


Relevant Topics

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...